معرفی
Dr. Andrew Morrow is an Honorary Clinical Lecturer at the University of Glasgow's School of Cardiovascular & Metabolic Health, affiliated with the British Heart Foundation (BHF) Glasgow Cardiovascular Research Centre. His research focuses on cardiovascular diseases, particularly microvascular angina, post-COVID-19 cardiac complications, and ischemic heart disease mechanisms. He leads and collaborates on clinical trials such as the PRIZE trial (evaluating Zibotentan) and the CISCO series (assessing long-term effects of SARS-CoV-2). His work bridges translational research and clinical practice, addressing novel therapies for non-obstructive coronary artery disease and post-viral cardiac syndromes.
Key contributions include studies on oxygen therapy for myocardial infarction, exercise stress testing in angina, and vascular mechanisms underlying post-COVID-19 conditions. His articles emphasize rho-kinase as a therapeutic target and cardio-renal interactions in multisystem illnesses. He has pioneered protocols for coronary vascular function assessment and mechanistic studies of endothelin SNPs in angina. His research also addresses socioeconomic disparities in post-hospitalization outcomes and glucose-lowering therapies in chronic kidney disease.
Dr. Morrow actively participates in international conferences (e.g., American Heart Association, British Cardiovascular Society) and collaborates with global teams on proteomic surrogates for cardiovascular outcomes. His work spans clinical trials, observational studies, and systematic reviews, contributing to precision medicine in cardiovascular care.
